TRADITIONDATA
10.10.2022 13:43:42 CEST | Business Wire | Pressemeddelelse
TraditionDATA, data- og informationsserviceafdelingen hos Compagnie Financière Tradition (Tradition), har udgivet en omfattende skandinavisk datapakke som svar på den stigende efterspørgsel på Traditions markedsførende prisdata i regionen.
Den fulde pakke af skandinaviske data, som indeholder data om valuta (FX), rentederivater (IRD) og inflation, er baseret på en kombination af priser, der tager udgangspunkt i aktiehandler foretaget af Traditions markedsførende mæglere samt deres ekspertanalyser. Dataene er tilgængelige direkte fra TraditionDATA såvel som på Refinitiv under firmaets regionale markedsdatapakker.
Udgivelsen af den skandinaviske datapakke er i tråd med TraditionDATAs mission om at tilbyde mindre, granulære pakker baseret på valuta, region eller produkt, som gør det muligt for kunderne kun at betale for det, de rent faktisk har brug for. Dette er i direkte modsætning til mange af deres konkurrenter, som kun tilbyder større europæiske pakker, som er dyre og tager tid at analysere nærmere, før de kan konverteres til brugbar forretningsindsigt.
Den skandinaviske datapakke giver kunderne mulighed for at analysere:
- FX - spothandler, krydshandler (cross trades), terminshandler på ydelser og produkter og kvartalsindtjening på tværs af DKK, NOK og SEK på det internationale valutamarked
- IRD - basisderivater, krydsvalutaderivater, renteswaps, overnight indexed swaps, terminskursaftaler
- Inflation - forbrugerprisindeksdata om inflation
Udover at tilbyde kunderne avancerede data og ekspertise i den skandinaviske region, muliggør TraditionDATA også streaming i realtid, øjebliksbilleder af dag til dag-renter, adgang til historiske data og fuld integration med eksisterende arbejdsgange.
James Watson, Global Head of Sales hos TraditionDATA, kommenterede: “Hos TraditionDATA ved vi, at der ikke findes to ens virksomheder, og derfor arbejder vi sammen med vores kunder om at udvikle pakker, der er skræddersyede til deres individuelle behov. Vi tror på, at regionale markeder fortsat vil kræve specifikke datasæt, der er lokaliseret til deres overordnede forretningsaktiviteter, og denne tilgang har allerede vist sig at være en stor succes i forbindelse med vores japanske Nihon- og israelske Shekel-pakker. Vi ser frem til at fortsætte med at tilføje nye instrumenter til den skandinaviske pakke og udvide vores regionale markedsdatatilbud i de kommende måneder.”
ENDS
Om TraditionDATA
TraditionDATA tilbyder en varieret og fleksibel tilgang til leverance af markedsdata på tværs af alle aktivklasser på det globale uofficielle børsmarked for derivater.
Ved at tilbyde mindre, mere fokuserede og granulære pakker baseret på valuta, region eller produkt sætter TraditionDATA sine kunder i stand til at betale for netop det, de har brug for, i modsætning til større pakker, der kræver nærmere analyse.
Med over 1 billion datapunkter på tværs af mere end 200 produkter og 186.000 instrumenter, der går mere end 15 år tilbage, samt 43 kontorer i 30 lande, tilbyder TraditionDATA aktører på tværs af det globale finansmarked alle de oplysninger, de har brug for, for at drive deres forretning og tage forretningsmæssige beslutninger, på grundlag af et stadigt voksende datasæt.
TraditionDATA er en del af Tradition (Compagnie Financière Tradition S.A. (SWX: CFT)), en af verdens største børsmæglere inden for finansielle og råvarerelaterede produkter på det uofficielle børsmarked for værdipapirer. Traditions lange historie med administration af prissætning af likviditet og afvikling af handler på tværs af flere aktivklasser med både nye og komplekse produkter på primære og nye vækstmarkeder gør det muligt for TraditionDATA at prisfastsætte finansielle instrumenter på mange af verdens mest omskiftelige markeder, som andre ikke formår.
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
For at se dette indhold fra cts.businesswire.com, så skal du give din accept på toppen af denne side.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20221010005055/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Danish C-UAS Startup Shotling Raises €700K Oversubscribed Pre-Seed (Myriad-IPO CLUB-EIFO) for Anti-Drone Shotgun2.2.2026 07:35:00 CET | Press release
Shotling, a Danish defense technology startup specializing in kinetic short-range counter-UAS (C-UAS) systems, today announced the closing of a pre-seed financing round with €700K committed out of a targeted €500K. The round is led by Myriad Defense Fund, with co-investment from IPO CLUB’s Fund II America 2030, and a non-dilutive match-loan granted by EIFO, the Export and Investment Fund of Denmark, supporting Shotling’s mission to deliver rapid-fire modular shotgun systems against FPV drones and loitering munitions—as the global counter-UAS market accelerates towards $10B by 2030, with kinetic defense segment showing strong momentum (25%+ CAGR). Shotling’s rotary shotgun system provides unmatched close-range defense (50–100m) against the rapidly growing threat of kamikaze drones, combining a gatling-style design, with novel, high-capacity magazines, and firing rates up to 3,000 RPM using standard or tungsten-based 12-gauge shells. With deep expertise in weapons engineering and active
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union1-3 Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation
High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 08:00:00 CET | Press release
Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
